Balancing Bleeding Risk and Thromboembolic Complications in Elderly Chronic Subdural Hematoma Patients Undergoing Burr Hole Trephination : A Multicenter Retrospective Cohort Study and Literature Review

• Published in: Journal of Korean Neurosurgical Society Vol. 66; no. 6; pp. 726 - 734
• Main Authors: Eun, Jin, Ahn, Stephen, Lee, Min Ho, Choi, Jin-Gyu, Park, Jae-Sung, Cho, Chul Bum, Kim, Young Il
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Neurosurgical Society 01.11.2023; 대한신경외과학회
• Subjects: Clinical; 신경외과학; Antithrombotic agent; Treatment outcome; Complications; Hematoma, subdural, chronic; Trephination
• ISSN: 2005-3711; 1598-7876
• DOI: 10.3340/jkns.2023.0115

Chronic subdural hematoma (CSDH) patients using anti-thrombotic agents (AT) at high risk for cardiovascular disease (CVD) are increasing. The authors aimed to analyze the factors influencing outcome by targeting patients using AT and to establish a desirable treatment strategy. A retrospective analysis was performed on data from 462 patients who underwent burr hole trephination (BHT) surgery for CSDH at five hospitals from March 2010 to June 2021. Outcomes included incidence of postoperative acute bleeding, recurrence rate, and morbidity or mortality rate. Patients were divided into the following four groups based on their history of AT use: No AT. Only antiplatelet agents (AP), only anticoagulants (AC), both of AP and AC. In addition, a concurrent literature review was conducted alongside our cohort study. Of 462 patients, 119 (119/462, 25.76%) were using AT. AP prescription did not significantly delay surgery (p = 0.318), but AC prescription led to a significant increase in the time interval from admission to operation (p = 0.048). After BHT, AP or AC intake significantly increased the period required for an in-dwelling drain (p = 0.026, 0.037). The use of AC was significantly related to acute bleeding (p = 0.044), while the use of AP was not (p = 0.808). Use of AP or AC had no significant effect on CSDH recurrence (p = 0.517, 1.000) or reoperation (p = 0.924, 1.000). Morbidity was not statistically correlated with use of either AP or AC (p = 0.795 and 0.557, respectively), and there was no significant correlation with mortality for use of these medications (p = 0.470 and 1.000). Elderly CSDH patients may benefit from maintenance of AT therapy during BHT due to reduced thromboembolic risk. However, the use of AC necessitates individualized due to potential postoperative bleeding. Careful post-operative monitoring could mitigate prognosis and recurrence impacts.